Seeking AlphaQwen · 实盘不做把握 4/10不做原因:无法执行
北京时间·🕒 发布 03:48:08(美东 08-25 15:48)·⟳ 抓取 03:49:06 +58s·⚡ 决策 08-26 03:51:02 +1m56s·62.6 天前
药明生物2026上半年业绩：收入118亿元人民币同比增18.4%，调整后净利润同比增38.6%，在手订单251亿美元
业绩表面强劲（收入+18.4%、调整后净利+38.6%、订单+30%），但三项关键工具（行情、Web搜索、KB）全部不可用：①无法获取一致预期判断是否存在真正surprise（经验核心：名义增长不是催化，超预期才是）；②无法获取2269.HK/WXXWY.US实时价格，无法设定入场、止损和仓位；③无法检索历史先例校准涨幅。按规则，stock_quote未返回ok且无真实价进quotes_used的标的不得ENTER。
📄 原文Seeking Alpha↗ 原文
Wuxi Biologics ADR Non-GAAP EPS of $0.81, revenue of $11.78B
- Wuxi Biologics ADR press release (WXXWY): 1H Non-GAAP EPS of $0.81. - Revenue of $11.78B. - Revenue of RMB 11.8 billi…
不做 药明生物（02269.HK）
行情服务完全不可用，无法获取实时价格、走势和市值，不满足ENTER的必要条件（真实价格已进quotes_used）；且港股当前未开盘，下一交易日开盘前仍无法验证价格
不做 药明生物ADR（WXXWY.US）
虽然美股当前盘中且理论上可交易，但行情服务连接被拒绝，无法获取WXXWY实时价格；同时无法确认业绩是否超出一致预期（Web/KB均不可用），无法判断是否存在真正的预期差edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
药明生物1H2026业绩绝对数字强劲（收入+18.4%、调整后净利+38.6%、backlog $251亿、新项目+43%），方向明确为正面。但交易执行需要：1）确认业绩相对一致预期的beat幅度（当前无法获取）；2）实时价格设定入场/止损（行情服务连接被拒绝）；3）历史先例校准涨幅量级（Web搜索不可用）。在无法验证预期差、无法获取任何真实价格的情况下，按纪律输出AVOID。
🔎 新鲜度:最早出现 2026-08-25 · 扩散 low · price-in 风险 medium ↗
消息传播链
- Seeking Alpha转载公司新闻稿摘要，为当前可见最早传播节点；因Web搜索不可用，无法确认港交所原始公告精确时间市场反应:未知（行情服务不可用）
关键理由
- 业绩绝对增长强劲：收入+18.4%、调整后净利+38.6%、毛利率扩张350bps，显示CDMO需求旺盛和运营效率提升
- 在手订单$251亿、3年内$55亿（+30%），新项目+43%、Win-the-Molecule+78%，未来收入可见性高
- 连续5年正自由现金流，财务质量改善，估值重估有基本面支撑
主要风险
- 无法确认业绩是否超出市场一致预期——若市场已充分定价该增速，则无增量edge
- 行情服务不可用，无法验证近期股价是否已提前反映预期（抢跑风险未知）
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
KB服务不可用（连接被拒绝），无法检索反向证据
检索:药明生物 2026 中期 利空 下调 风险
先例如何影响了这次决策
对本次决策的影响:因Web搜索和行情服务均不可用，无法检索和验证任何历史先例，也无法调用event_study计算价格反应
方向:无先例数据
涨幅量级:无法校准
形态:无法判断
工具调用 · 历史记录,结果未知(7 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- web_search · 结果未知
- search_case_library · 结果未知
- kb_search · 结果未知
- direct_instrument_candidates · 结果未知
原文全文
展开原文 · 1,365 字
- Wuxi Biologics ADR press release (WXXWY): 1H Non-GAAP EPS of $0.81.
- Revenue of $11.78B.
- Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD)
- IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds
- EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted EBITDA grew 24.9% and adjusted net profit rose 38.6% YoY
- Earnings per share increased 3.4% YoY; adjusted earnings per share grew 37.3% YoY
- Free cash flow reached RMB 1.5 billion in H1 2026, positive free cash flow for five consecutive years
- Total backlog increased to US$25.1 billion; backlog within 3 years increased to US$5.5 billion, up ~30% YoY
- Record-high 123 new organic integrated projects added in H1 2026 (+43% YoY); WuXi XDC's BioDlink acquisition brought 46 new integrated projects bringing Group's total to 1,064; 70%+ of the new adds and 50%+ of the total projects were complex biologics modalities
- 16 Win-the-Molecule projects in H1 2026, up 78% YoY, including 4 Phase III and 1 commercial; cumulative Win-the-Molecule projects reached 128 since 2018
- 68 INDs filed in H1 2026; expanding IND filing capacity to 300 per year (+50%) by 2027
- 34 PPQs scheduled for 2026 and 30 more for 2027 as of June 2026; 100% PPQ campaign success rate achieved to date
-
- Revenue of $11.78B.
- Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD)
- IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds
- EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted EBITDA grew 24.9% and adjusted net profit rose 38.6% YoY
- Earnings per share increased 3.4% YoY; adjusted earnings per share grew 37.3% YoY
- Free cash flow reached RMB 1.5 billion in H1 2026, positive free cash flow for five consecutive years
- Total backlog increased to US$25.1 billion; backlog within 3 years increased to US$5.5 billion, up ~30% YoY
- Record-high 123 new organic integrated projects added in H1 2026 (+43% YoY); WuXi XDC's BioDlink acquisition brought 46 new integrated projects bringing Group's total to 1,064; 70%+ of the new adds and 50%+ of the total projects were complex biologics modalities
- 16 Win-the-Molecule projects in H1 2026, up 78% YoY, including 4 Phase III and 1 commercial; cumulative Win-the-Molecule projects reached 128 since 2018
- 68 INDs filed in H1 2026; expanding IND filing capacity to 300 per year (+50%) by 2027
- 34 PPQs scheduled for 2026 and 30 more for 2027 as of June 2026; 100% PPQ campaign success rate achieved to date
-
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。